Consequently, GLP-1 and its long lasting analogues are currently considered an effective therapy for T2D, and have been demonstrated to stimulate a range of anti-diabetic effects including: an increase in satiety; inhibition of food motivated ‘behaviour’ and a reduction in gastric emptying [59,60]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.